Last reviewed · How we verify
NCT07273084: MICNP
Multidisciplinary Intervention for Non-Cancer Chronic Pain: Pilot Study
NA trial testing Multidisciplinary Intervention Program for Chronic Non-Cancer Pain in Non-cancer Pain in 12 participants. Participants enrolled and being followed up; not accepting new ones.
1 September 2025
Quick facts
| Lead sponsor | Victor Ortiz Mallasen |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 1 July 2025 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 March 2026 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Multidisciplinary Intervention Program for Chronic Non-Cancer Pain
Conditions studied
- Non-cancer Pain — all drugs for Non-cancer Pain →
- Chronic Non-cancer Pain — all drugs for Chronic Non-cancer Pain →
Sponsor
Victor Ortiz Mallasen
Who can join
Adults 18 to 79, any sex, with Non-cancer Pain or Chronic Non-cancer Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Introduction: Non-cancer chronic pain (NCCP) persists beyond the injury that caused it, affecting approximately 20% of the global population (around 1.6 billion people) and 17-18% in Spain (about 8 million people). Its treatment is complex and often insufficient, highlighting the need for an integrated, multimodal, multidisciplinary approach coordinated between primary and hospital care. Objective: To evaluate the effectiveness of a multidisciplinary intervention program combining pain neuroscience education, therapeutic physical exercise, and promotion of healthy habits, aiming to improve health-related quality of life in individuals with NCCP at the Benicàssim Health Center. Methodology: This is a quasi-experimental, before-and-after pilot study, non-randomized, without a control group, using a convenience sample of 12 participants. Sociodemographic, health-related, and clinical variables will be measured, including health-related quality of life, central sensitization, kinesiophobia, catastrophizing, pain level, body mass index, sleep quality, perceived social support, anxiety, and depression. Measurements will be taken before the program, at completion, and at 3 months. The intervention is a 6-week group program with 17 sessions, combining pain neuroscience education, individualized therapeutic exercises, and promotion of healthy habits. Data will be analyzed using SPSS v.29 with a significance level of p\<0.05.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07273084
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07273084 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Victor Ortiz Mallasen
- Last refreshed: 17 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07273084.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing